Congressional Hearing on 340B Drug Pricing Program Improvements
January 1, 2019
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
The allows certain hospitals and clinics to purchase outpatient drugs at discounted prices, and this hearing explored how federal oversight and program rules impact the availability and cost of these medications for patients and healthcare providers.
Potentially affected actors named in the source documents. Mention is not a position.
Hospitals and Clinics
These entities participate in the 340B program to purchase discounted outpatient drugs.
Drug Manufacturers
These companies are required by law to provide drugs at specific discounted rates to eligible 340B entities.
Patients
Patients receiving care at 340B-eligible facilities may be impacted by how these facilities manage drug pricing and program participation.
Last recorded activity January 1, 2019.
Next step not available in the current record.
Summary
Why It Matters
The allows certain hospitals and clinics to purchase outpatient drugs at discounted prices, and this hearing explored how federal oversight and program rules impact the availability and cost of these medications for patients and healthcare providers.
Key Facts
- The hearing took place on July 11, 2018, in the Rayburn House Office Building.
- The hearing focused on identifying opportunities to improve the 340B Drug Pricing Program.
- Testimony was provided by representatives from the U.S. Government Accountability Office, Texas Oncology, Parkland Hospital, and the University of California, San Diego.
- Numerous organizations submitted written statements, including the Association of American Medical Colleges, 340B Health, and the Children's Hospital Association.
- The Community Oncology Alliance submitted an article regarding alleged abuse of the 340B program.
Frequently Asked Questions
What is the 340B Drug Pricing Program?
Who testified at this hearing?
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Focus on Program Oversight
The hearing highlights a shift toward increased scrutiny of the 340B program's operational integrity and potential for abuse.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy65Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools